New MolecuLight i:X® Upgrade Enables Faster, More Accurate Digital Wound Measurement
i:X Platform’s Precise Wound Measurement, along with Fluorescence Imaging, for More Accurate Detection and Ongoing Documentation of Wounds
TORONTO, Feb. 12, 2020 (GLOBE NEWSWIRE) — eSight Corporation, a leading vision enhancing platform, is pleased to announce the appointment of Robert Vaters as President and CEO effective February 3rd. In this role, Vaters will lead all strategic and business aspects of the company during its next stage of growth. Vaters is a C-Suite leader with extensive experience navigating organizations through the U.S. healthcare and technology industries.
“We have only begun to discover the transformative possibilities of our technology,” said Sam Ifergan, Executive Chairman of eSight. “Robert has the experience and track record to help eSight during its next stage of our growth and disrupt the vision healthcare industry.”
Toronto, CANADA – (February 20, 2020) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, released a significant upgrade to its i:X digital wound measurement feature that enables clinicians to more accurately and quickly capture digital wound area measurement. Specifically, clinicians can now reliably detect more complex wound borders using the i:X’sAuto Mode feature and can also now input a depth measurement.
“We and others have shown that standard of care length by width wound area measurements overestimate wound area measurements by more than 30%1, which is unacceptable for tracking wound progress over time”, says Danielle Dunham, Product Manager for the MolecuLight i:X platform. “With the upgrade to MolecuLight’s wound measurement feature, the device combines precise wound measurement with advanced fluorescence imaging for more accurate detection of wounds containing bacteria to empower clinicians with more information at the point of care for a more comprehensive wound assessment.”